

Tecaginlimab

Cat. No.:	HY-P99572
CAS No.:	2253891-70-0
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity ^[1] .	
IC ₅₀ & Target	CD40	4-1BB
In Vitro	Tecaginlimab binds to recombinant human CD40 and 4-1BB with affinities of 1.0 nM and 0.17 nM, respectively ^[1] . Tecaginlimab (0.001-1 µg/mL; 5 d) induces dendritic cell (DC) maturation in vitro ^[1] . Tecaginlimab (0.2 µg/mL; 10-15 d) enhances T-cell activation in vitro ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Tecaginlimab (0.0008-0.2 µg/mL; 4 d) enhances tumor-infiltrating lymphocyte expansion ex vivo ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Muik A, et, al. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity. J Immunother Cancer. 2022 Jun;10(6):e004322.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA